Increased serum levels of cyclophilin A and matrix metalloproteinase-9 are associated with cognitive impairment in patients with obstructive sleep apnea

2021 ◽  
Author(s):  
Mengfan Li ◽  
Hairong Sun ◽  
Tengqun Shen ◽  
Song Xue ◽  
Yang Zhao ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Cognitive Impairment ◽  
Sleep Apnea ◽  
Matrix Metalloproteinase ◽  
Cyclophilin A ◽  
Serum Levels ◽  
Matrix Metalloproteinase 9 ◽  
Obstructive Sleep ◽  
Metalloproteinase 9

Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome

2004 ◽  
Vol 170 (12) ◽  
pp. 1354-1359 ◽  
Author(s):  
Toshiyuki Tazaki ◽  
Kenji Minoguchi ◽  
Takuya Yokoe ◽  
Karen Thursday R. Samson ◽  
Hideko Minoguchi ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Matrix Metalloproteinase ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Matrix Metalloproteinase 9 ◽  
Obstructive Sleep ◽  
Apnea Syndrome ◽  
Metalloproteinase 9

scholarly journals Serum matrix metalloproteinase-9 activity in obstructive sleep apnea

2021 ◽  
Author(s):  
Aleksandra Franczak ◽  
Robert Skomro ◽  
Iwona Bil-Lula ◽  
Mark Fenton ◽  
Joshua Lawson ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Obstructive Sleep ◽  
Metalloproteinase 9

Lack of association of matrix metalloproteinase-9 promoter gene polymorphism in obstructive sleep apnea syndrome

2015 ◽  
Vol 43 (7) ◽  
pp. 1099-1103 ◽  
Author(s):  
Mustafa Yalcınkaya ◽  
Selim S. Erbek ◽  
Seda Turkoglu Babakurban ◽  
Elif Kupeli ◽  
Serife Bozbas ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Gene Polymorphism ◽  
Matrix Metalloproteinase ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Obstructive Sleep ◽  
Promoter Gene ◽  
Apnea Syndrome ◽  
Metalloproteinase 9

scholarly journals Matrix Metalloproteinase-9 Is a Predictive Factor for Systematic Hypertension and Heart Dysfunction in Patients with Obstructive Sleep Apnea Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Shuhui Wang ◽  
Shisheng Li ◽  
Bin Wang ◽  
Jiajia Liu ◽  
Qinglai Tang
Keyword(s):  
Obstructive Sleep Apnea ◽  
Risk Factor ◽  
Sleep Apnea ◽  
Cardiovascular Diseases ◽  
Matrix Metalloproteinase ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Obstructive Sleep ◽  
Apnea Syndrome ◽  
Metalloproteinase 9

Patients with obstructive sleep apnea syndrome (OSAS) showed higher prevalence in cardiovascular diseases due to aberrant hypoxia and oxidative stress. However, not all OSAS patients end up with cardiovascular disorders, and identification of novel biomarker will be invaluable for differentiating patients at risk. Here we tested the serum matrix metalloproteinase-9 (MMP-9) levels in 47 untreated OSAS patients and found that the MMP-9 level was positively correlated with severity of OSAS, which was consistent with hypoxia degree and duration. Besides, the MMP-9 level was higher in patients complicated with systematic hypertension (P < 0.001). Furthermore, we selected those OSAS patients without any cardiovascular dysfunction (n=35) and followed up for up to five years. By the end of follow-up, 12 patients had hypertension onset and 3 patients had left ventricular hypertrophy. By analyzing the clinical outcomes with MMP-9 expression, we demonstrated that high serum MMP-9 in OSAS patients was a risk factor for occurrence of cardiovascular diseases. In addition, we cultured the vascular endothelial cells (VEC) from rat aorta in hypoxia condition to investigate whether MMP-9 was elevated due to hypoxia in OSAS patients. Cellular results revealed that the expression, secretion, and activity of MMP-9 were all upregulated by hypoxia and can cleave the beta2-adrenergic receptor (β2AR) on VEC surface. Our results not only determined MMP-9 as a risk factor for cardiovascular diseases in OSAS patients, but also showed the possible involvement of hypoxia-MMP-9-β2AR signaling axis.

scholarly journals Little genomic support for cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers

2021 ◽  
Author(s):  
Emma L Anderson ◽  
Dylan M Williams ◽  
Venexia Walker ◽  
Neil M Davies
Keyword(s):  
Cognitive Impairment ◽  
Matrix Metalloproteinase ◽  
Drug Targets ◽  
Cyclophilin A ◽  
Matrix Metalloproteinase 9 ◽  
Synaptic Function ◽  
Polygenic Risk Score ◽  
Alzheimers Disease ◽  
Score Analysis ◽  
Metalloproteinase 9

AbstractTherapeutic targets for halting the progression of Alzheimers disease pathology are lacking. Recent evidence suggests that APOE4, but not APOE3, activates the cyclophilin A matrix metalloproteinase-9 (CypA MMP9) pathway in the cerebrospinal fluid, leading to an accelerated breakdown of the blood brain barrier (BBB) and thereby causing neuronal and synaptic dysfunction. Furthermore, blockade of the CypA MMP9 pathway in APOE4 knock-in mice restores BBB integrity and subsequently normalizes neuronal and synaptic function. Thus, CypA has been suggested as a potential target for treating APOE4 mediated neurovascular injury and the resulting neuronal dysfunction and degeneration. The odds of drug targets passing through clinical trials are greatly increased if they are supported by genomic evidence. We found little evidence that CypA or MMP9 affected the risk of Alzheimers disease or cognitive impairment using two-sample Mendelian randomization and polygenic risk score analysis in humans. This casts doubt on whether they are likely to represent effective drug targets for cognitive impairment in APOE4 carriers.

Sign in / Sign up

Export Citation Format

Share Document